New Perspectives on the Treatment of R/R MM: Case Discussion and Common Clinical Scenarios

Join us and expert hematologists for this webinar featuring case-based presentations and discussion on treatment of multiple myeloma in the relapse setting. Get up to date on strategies at early relapse and considerations for managing heavily pretreated disease.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introduction
  • Current Options in the Early Relapse Setting
  • Considerations for Managing Relapses in Heavily Pretreated Disease
  • Other Novel Therapies that will soon Change Practice
  • Audience Question and Answer Session


Sagar Lonial, MD

Professor and Chair 
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Goal Statement
The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma in the relapse setting.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for patients with MM in the relapse setting, based on current available data, individual patient and disease characteristics, and response to and tolerance of prior therapy
  • Evaluate the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Address challenges of access to CAR T-cell therapy and use of bridging strategies in patients with MM in the relapse setting
  • Mitigate treatment-related adverse events associated with new or novel MM treatments in the relapse setting
  • Identify patients with MM in the relapse setting who would be eligible for enrollment on clinical trials


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.